- Home
- CNR vs RNA Comparison
CNR vs RNA Comparison
Compare CNR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- RNA
- Stock Information
- Founded
- CNR 1864
- RNA 2012
- Country
- CNR United States
- RNA United States
- Employees
- CNR 2076
- RNA N/A
- Industry
- CNR Coal Mining
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- RNA Health Care
- Exchange
- CNR Nasdaq
- RNA Nasdaq
- Market Cap
- CNR 3.9B
- RNA 3.2B
- IPO Year
- CNR N/A
- RNA 2020
- Fundamental
- Price
- CNR $75.55
- RNA $26.66
- Analyst Decision
- CNR Strong Buy
- RNA Strong Buy
- Analyst Count
- CNR 3
- RNA 12
- Target Price
- CNR $108.00
- RNA $68.25
- AVG Volume (30 Days)
- CNR 1.1M
- RNA 1.9M
- Earning Date
- CNR 05-15-2025
- RNA 05-08-2025
- Dividend Yield
- CNR 0.14%
- RNA N/A
- EPS Growth
- CNR N/A
- RNA N/A
- EPS
- CNR 9.61
- RNA N/A
- Revenue
- CNR $2,193,231,000.00
- RNA $10,897,000.00
- Revenue This Year
- CNR $93.87
- RNA N/A
- Revenue Next Year
- CNR $7.53
- RNA $135.33
- P/E Ratio
- CNR $7.86
- RNA N/A
- Revenue Growth
- CNR N/A
- RNA 13.98
- 52 Week Low
- CNR $58.19
- RNA $21.51
- 52 Week High
- CNR $134.59
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- CNR N/A
- RNA 45.21
- Support Level
- CNR N/A
- RNA $25.28
- Resistance Level
- CNR N/A
- RNA $27.67
- Average True Range (ATR)
- CNR 0.00
- RNA 2.36
- MACD
- CNR 0.00
- RNA -0.03
- Stochastic Oscillator
- CNR 0.00
- RNA 56.41
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.